its oncogenic potential is suppressed. 8 In some cancer cells, the csrc gene is not mutated, but c-Src function is nonetheless upregulated. 9 It is thought that disruption of the strict regulation of c-Src signaling could trigger cancer progression; however, the underlying mechanisms remain unclear. Once activated, c-Src acts as a common relay point for several downstream cascades from extracellular signals, such as growth factors and integrins, to intracellular signaling pathways. 5, 10 c-Src is a member of the Src family of kinases (SFKs), which comprises 8 members in mammals: c-Src, Fyn, c-Yes, Lyn, Lck, Hck, c-Fgr, and Blk. 11 Among those, c-Src and c-Yes are frequently upregulated in a variety of human cancers. 5, 7 The distinctive expression patterns and functional redundancy of SFK members have hampered concurrent analyses of their contributions to cancer progression. Previously, we showed that the oncogenic function of c-Src is spatially regulated, and that c-Src-mediated cell transformation is initiated from nonraft compartments. 12, 13 Based on these findings, we recently identified a critical substrate for c-Src in nonraft compartments and showed that Fer tyrosine kinase is a key mediator of c-Src-induced cell transformation. 14 In addition,
we found that Fer is involved in tumorigenesis and invasiveness in some cancers in which c-Src is upregulated. Indeed, upregulation of Fer has been implicated in tumor progression in various human cancers; however, the mechanism underlying upregulation remains unknown. [15] [16] [17] [18] [19] MicroRNAs (miRNAs) are a family of small, endogenous, evolutionarily conserved noncoding RNAs involved in the regulation of expression of target mRNAs. 20, 21 MicroRNAs control diverse cellular functions and fine-tune various signaling pathways. 22 MicroRNAs are extensively dysregulated in several human cancers and act as key regulators of complex signaling networks by altering expression of oncogenes or tumor suppressor genes. [23] [24] [25] To verify the molecular mechanisms underlying c-Src-mediated cell transformation, we previously developed a model system using Csk-deficient mouse embryonic fibroblasts (Csk −/− cells), which can be transformed by c-Src. 26 A series of studies showed that this system is useful for the identification of critical pathways leading to c-Src-induced cell transformation. Using this system, we focused on the contribution of miRNAs and uncovered miR-NA-mediated c-Src oncogenic signaling and cross-talk between c-Src and other oncogenic signaling networks, including the focal adhesion-mediated pathways, microRNA (miR)-542-3p-ILK, miR-27b-paxillin, and the mTOR pathways, and miR-99a-mTOR and miR-424/503-Rictor. [27] [28] [29] [30] [31] In contrast, we also found that expression of c-Src is regulated by miR-137, which is substantially downregulated in many cancers. 32 
| MATERIAL S AND ME THODS

| MicroRNA microarray analysis
MicroRNA microarray experiments were carried out using Agilent
Mouse miRNA microarrays, catalogued in the Sanger database version 16.0 (design ID 031184). Briefly, 100 ng total RNA was labeled with pCp-Cy3 using the miRNA Labeling Reagent and Hybridization Kit (Agilent Technologies). Images were extracted using Agilent Feature Extraction software (version 10.7.3.1). Agilent GeneSpring GX software (version 14.9.1) was then used to calculate the betweensample fold change by one-way ANOVA (P < .1) with BenjaminiHochberg correction for multiple testing.
| Gene expression microarray analysis
Briefly, 500 ng total RNA was reverse transcribed into doublestranded cDNA using AffinityScript multiple temperature reverse transcriptase (Agilent Technologies). The resulting complementary
RNAs were labeled with cyanine-3 (Perkin Elmer) using the Low Input Quick-Amp Labeling kit (Agilent Technologies). Hybridizations were undertaken on Agilent SurePrint G3 Mouse GE 8 × 60K Microarrays (design ID 028005). Agilent GeneSpring GX software (version 14.9.1) was used to calculate the between-sample fold change (P < .1; twotailed Student's t test).
Other methods are described in Document S1. 
| RE SULTS
| MicroRNA-129-1-3p targets c-Src/c-Yes/Fer
To verify the function of miR-129-1-3p, we examined the effect of miR-129-1-3p on Src-related signaling. In HCT116 cells, as well as In 9 paired noncancerous/cancer colon tissues, miR-129-1-3p was significantly downregulated relative to paired noncancerous tissues (P = .02373) ( Figure 6C ). These observations suggest that downregulation of miR-129-3p is associated with a wide array of human cancers in which SFK signaling is upregulated.
| D ISCUSS I ON
Previously, to elucidate the molecular mechanisms underlying the early phases of c-Src-induced transformation, we established an experimental system using an inducible c-Src expression system in Cskdeficient cells. 33 Here, we used this system to study the potential has been observed in some types of cancers, including gastric, hepatocellular, and pancreatic cancer. [38] [39] [40] [41] Previous studies showed that miR-129-1-3p was downregulated by DNA methylation, 41 
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